Why the study?
Heart failure carries high hospitalization rates and poor prognosis, while novel emerging therapies are changing the drug treatment paradigm.
The review highlights key 2020 updates in heart failure drug therapy, emphasizing the expanding roles of ARNI, SGLT2i, GLP-1 RA, vericiguat, and mavacamten.
Answers are grounded in this paper and cite their sources.
May inform awareness of emerging HF/HCM therapies; leaves open prospective validation before practice change.
心力衰竭（心衰）患者住院率高、预后不良，是心血管病领域备受关注的严重临床综合征。近年来涌现出一批新型的治疗心衰的药物，改变着心衰药物治疗的模式。沙库巴曲缬沙坦已成为心衰治疗的基石，院内早期应用可减少心衰患者近期心血管不良事件，长期应用可维持甚至逆转心室重构，射血分数保留的心衰患者亦具有潜在获益。钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂具有心血管保护作用，具有降低心衰患者糖尿病发病率、延缓糖尿病肾病进展、减少心血管事件发生等多重获益。在心衰标准治疗基础上加用新型可溶性鸟苷酸环化酶激动剂维利西呱可进一步降低不良事件的发生率，是心衰药物治疗的重要补充。心肌肌球蛋白抑制剂mavacamten可通过降低心肌收缩力改善肥厚型心肌病患者心功能，有望改写其治疗模式。.
No takes yet. Share an insight, caveat, or question.
He et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: